(Q34781949)

4 August 2017

0 references

1 reference

title

Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials (English)

1 reference

4 August 2017

0 references

1 reference

E Mannucci

1

1 reference

4 August 2017

M Monami

2

1 reference

4 August 2017

C Lamanna

3

1 reference

4 August 2017

G F Gensini

4

1 reference

4 August 2017

N Marchionni

5

1 reference

4 August 2017

publication date

26 May 2008

1 reference

Diabetes, Obesity and Metabolism

4 August 2017

published in

1 reference

4 August 2017

volume

10

1 reference

4 August 2017

issue

12

1 reference

4 August 2017

page(s)

1221-1238

1 reference

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, para

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

The insulin sensitiser pioglitazone does not influence skin microcirculatory function in patients with type 2 diabetes treated with insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

The effect of pioglitazone on the liver: role of adiponectin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Diabetes treatments have differential effects on nontraditional cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Comparison of pioglitazone and metformin efficacy using homeostasis model assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monother

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-alpha levels in Type 2 diabetic patients: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Effects of pioglitazone on fasting and postprandial levels of lipid and hemostatic variables in overweight non-diabetic patients with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Effects of pioglitazone in familial combined hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Pioglitazone Increases Serum Magnesium Levels in Glucose-Intolerant Subjects. A Randomized, Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

The DREAM trial – Authors' reply

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

Effect of Rosiglitazone on Endothelial Function and Inflammatory Markers in Patients With the Metabolic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00892.X

10.1111/J.1463-1326.2008.00892.X

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference